Jonathan Heller

Jonathan serves as an Entrepreneur in Residence at Celdara Medical and is primarily responsible for building a new business around one of CM’s lead therapeutic platforms. He also assists with sourcing and evaluating other technologies for the CM pipeline.

Jonathan has spent over 20 years building biotechnology company pipelines by leading drug and business development efforts at companies including BioMarin, Synageva, and Pfizer. Among his accomplishments is leading the preclinical development of BioMarin’s Brineura and Vosoritide, the first ever approved treatments for late infantile neuronal ceroid lipofuscinosis and achondroplasia. He also led the initial development of Valoctocogene roxaparvovec, the first approved gene therapy for Hemophilia type A. He has been a founder of three biotech startup companies. Jonathan began his industry career by cofounding a company to develop the oncology drugs he discovered while a graduate student. He has earned an MBA from The University of California at Berkeley, a PhD in biology from The Johns Hopkins University, and a BA in Biochemistry and Molecular Biology from Reed College.